NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J
Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9000
Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer. Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0349
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-N0349
Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer. Kim, G. , Marsoni, S. , Monges, G. , Allegra, C. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N994C
Phase II trial of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer Mcwilliams, R. , Goetz, M. , Morlan, B. , Salim, M. , Rowland, K., Jr ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0341
Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB) Meropol, N. J. , Niedzwiecki, D. , Shank, B. , Colacchio, T. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2005 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-9281
Use of the ratio of metastatic to examined lymph nodes to predict local recurrence in rectal cancer: Analysis of data from intergroup trial 0114. Meyers, M. O. , Hollis, D. R. , Mayer, R. J. , Goldberg, R. M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - INT-0114
Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): Findings from NCCTG N9741. Sargent, D. J. , Campbell, M. E. , Grothey, A. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Evaluation of recurrence rate,time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair. Sinicrope, F. , Foster, N. R. , Sargent, D. J. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N994C
